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Abstract
Poly(ADP-ribose) polymerase 1 (PARP1) is a key player in DNA repair, genomic stability
and cell survival and it emerges as a highly relevant target for cancer therapies. To deepen
our understanding of PARP biology and mechanisms of action of PARP1-targeting anti-can-
cer compounds, we generated a novel PARP1-affinity reagent, active both in vitro and in
live cells. This PARP1-biosensor is based on a PARP1-specific single-domain antibody
fragment (~ 15 kDa), termed nanobody, which recognizes the N-terminus of human PARP1
with nanomolar affinity. In proteomic approaches, immobilized PARP1 nanobody facilitates
quantitative immunoprecipitation of functional, endogenous PARP1 from cellular lysates.
For cellular studies, we engineered an intracellularly functional PARP1 chromobody by
combining the nanobody coding sequence with a fluorescent protein sequence. By follow-
ing the chromobody signal, we were for the first time able to monitor the recruitment of
endogenous PARP1 to DNA damage sites in live cells. Moreover, tracing of the sub-nuclear
translocation of the chromobody signal upon treatment of human cells with chemical sub-
stances enables real-time profiling of active compounds in high content imaging. Due to its
ability to perform as a biosensor at the endogenous level of the PARP1 enzyme, the novel
PARP1 nanobody is a unique and versatile tool for basic and applied studies of PARP1 biol-
ogy and DNA repair.
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Introduction
Poly(ADP-ribose) polymerase (PARP) proteins are involved in DNA repair, gene expression
regulation, genomic stability and cell death. Human PARP family comprises 17 members, out
of which PARP1 is the most abundant and best characterized. Due to its critical role in the
repair processes of DNA strand breaks, PARP1 became an important target for drug discovery
in cancer therapeutics. Human PARP1 is a 113 kDa protein consisting of three main domains:
an N-terminal DNA-binding domain (containing three zinc fingers) [1, 2], a central automodi-
fication domain and a C-terminal catalytic domain [3, 4].
Upon DNA damage, PARP1 is recruited to DNA lesions [5], where it binds DNA through
its N-terminal zinc finger motives [6]. Subsequently, PARP1 mediates the process of PARyla-
tion using nicotinamide adenine dinucleotide (NAD+) as a substrate to catalyze the covalent
transfer of ADP-ribose units to a variety of nuclear acceptor proteins such as transcription fac-
tors, histones, DNA repair enzymes and PARP1 itself [7, 8]. This PARylation triggers local
relaxation of the chromatin structure and recruitment of the DNA repair machinery (XRCC1,
DNA ligase III, DNA polymerase ß, Ku70) [9].
Blocking DNA repair is an attractive strategy for sensitizing cancer cells to radio- and/or
chemotherapy, and being at the initiating point of the DNA repair cascades, PARP1 is a valid
target for these strategies. Several PARP-specific inhibitors have been developed up to date;
including niraparib (MK-4827), olaparib (AZD-2281) and veliparib (ABT-888) which are cur-
rently tested in clinical studies. These inhibitors are especially potent when applied to breast
cancer gene (BRCA) deficient cells, in which they induce synthetic cytotoxicity [10]. However,
the results of the clinical studies are so far contradictory. Furthermore, the molecular mecha-
nisms of action of the PARP-targeting compounds (e.g. catalytic inhibition, or additional
PARP1-“trapping”) require additional investigation.
Due to the utmost importance of understanding the biology of PARP for unraveling the
principles of DNA repair and for developing cancer-targeting therapies, there is ongoing need
for reliable research tools addressing PARP1 dynamics. So far, common approaches for
microscopy-based examination of PARP localization and dynamics rely on staining of endoge-
nous PARP1 with specific antibodies in fixed cells or on heterologous expression of chimeric
fluorescent fusion constructs (e.g. GFP-PARP1). Notably, immunostaining procedures are not
free from aberrations or artifacts, depending on the fixation and permeabilization methods and
on the antibodies of choice [11, 12]. This problem is especially relevant for PARP detection, as
several PARP-specific antibodies have shown different subnuclear localization at different con-
centrations of PFA [13–16]. On the other hand, ectopically expressed fluorescent PARP1-fu-
sion proteins might not reflect the behavior of their endogenous counterpart. Overexpression
of PARP1 changes the intracellular PARP1 level and therefore might have an impact on
PARP1 cellular distribution and function.
Taken together, until now there was no tool available which would enable live-cell detection
of endogenous PARP1. To overcome this technical limitation, we took advantage of single-
domain camelid antibodies. Heavy-chain only antibodies contain the smallest naturally occur-
ring antigen-binding domain, which is comprised of only one polypeptide chain. This domain
is termed variable domain of heavy-chain antibodies (VHH), or simply “nanobody”. The
advantage of nanobodies lies in their single-domain nature, stability, solubility and small size.
These binding molecules are only 15 kDa in size and functional in the reducing environment
of the cytoplasm, as has been recently shown [17–20].
Here, we focused on the characterization of a newly developed PARP1-specific nanobody
and on its performance in the following techniques and applications: immunoprecipitation,
live-cell imaging and high content analysis (HCA). We discuss the advantages of the PARP1
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nanobody compared to conventional PARP1 immunoreagents in the tested applications. Fur-
thermore, we demonstrate that our PARP1 nanobody enables live-cell immunodetection of
endogenous PARP1 dynamics, previously not possible with existing reagents and methods.
Materials and Methods
VHH library and screening
One alpaca (Vicugna pacos) was immunized with purified autoPARylated hPARP1 protein
according to the protocol described previously [21]. Alpacas belong to Livestock Center of the
Faculty of Veterinary Medicine, Ludwig Maximilians University, Munich. Immunization was
performed in strict accordance with the German Animal Welfare Law and has been approved
by the government of Upper Bavaria (Permit number: 55.2-1-54-2531.6-9-06). 70 days after
the first immunization, ~100 ml blood was collected from the animal and lymphocytes were
isolated by Ficoll gradient centrifugation using the Lymphocyte Separation Medium (PAA Lab-
oratories GmbH). 1x 107 B-cells were used to prepare total RNA using the Nucleospin RNA
Kit (Macherey-Nagel). Complementary DNA (cDNA) was amplified using the First-Strand
cDNA Synthesis Kit (GE Healthcare) according to the manufacturer´s protocol. The VHH rep-
ertoire was amplified from the cDNA by 3 subsequent nested PCR reactions using 6 different
VHH-specific primers [17]. The VHH library was subcloned into the SfiI/NotI sites of the
pHEN4 phagemid vector and transformed into E. coli TG1 cells [22]. E. coli cells were further
infected with M13K07 helper phages to produce phages carrying VHHs on their tips. The
phage display/immunopanning procedures and ELISA were performed as detailed in [23]. For
further studies, a VHH with the highest solubility and affinity to PARP1 was selected.
Expression plasmids
For bacterial expression of the VHH domain (nanobody), the sequence were cloned into the
pHEN6 vector [22], thereby adding a C-terminal 6xHis-tag for IMAC purification. Bacterial
expression vector of PARP1 VHH will be provided upon request to the authors by ChromoTek
via MTA (material transfer agreement). For protein production, E. coli JM109 cells (NEB) were
used. Expression and purification of the nanobody was carried out as described previously
[24]. For mammalian expression of PARP1 chromobody, N-terminal fusions of the PARP1
nanobody to the fluorescent proteins TagGFP2 or TagRFP (Evrogen) were constructed using
BglII/HindIII restriction sites in the target backbone vector. PARP1 Chromobody vector will
be provided upon request to the authors by ChromoTek via MTA. All resulting constructs
were sequenced and tested for expression in HEK293T cells followed by immunoblot analysis.
Mammalian expression plasmids of GFP-hPARP1, GFP-hPARP2, GFP-hPARP3 and GFP-
hPARP9 were kindly provided by Prof. Heinrich Leonhardt, LMUMunich. The plasmids cod-
ing for the GFP- or mCherry-tagged PARP1 domains (DBD-GFP, ZnF1-GFP, ZnF2-GFP,
mCherry-ZnF3, WGR-PARP domain-mCherry) were kindly provided by Gyula Timinszky,
LMUMunich. SF9 insect cells expressing Strep-tagged human PARP1 domains (DNA-binding
domain, automodification domain, catalytic domain) where kindly provided by Annette
Becker, TU Darmstadt. Point mutations were introduced into the human ZnF2 sequence with
the Q51 site-directed mutagenesis kit (NEB) according to the manufacturer’s instructions.
Antibodies and chemical compounds
The following primary antibodies were used: rat anti-GFP clone 3H9 (ChromoTek), mouse
anti-RFP clone 3F5 (ChromoTek), rabbit anti-TagRFP (Evrogen, AB233), mouse anti-PARP1
clone CII-10 (BD-Biosciences), mouse anti-pADPr clone 10H (Santa Cruz) and rabbit
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anti-GAPDH antibody (Santa Cruz, sc 25778). The following secondary antibodies were used
for detecting the primaries: anti-rat/mouse/rabbit-Alexa Fluor 647/568/488 (Cell Signaling).
The following small molecule compounds were administered: camptothecin (Tocris), actino-
mycin D (Sigma), 4-NQO (Sigma) and H2O2 (Sigma). The following affinity resins were used
for immunoprecipitation: GFP-Trap1, RFP-Trap1 and PARP1 nanotrap (ChromoTek).
PARP1-affinity resin generation and immunoprecipitation
Purified VHH was covalently coupled to Sepharose beads (GE Healthcare) via NHS according to
the manufacturer´s protocol, creating so-called PARP1 nanotrap. For immunoprecipitation, 1 x
106–1 x 107 HEK293T, HeLa, MEF or BHK cells expressing the target protein were washed and
harvested in phosphate buffered saline (PBS). Cell pellets were homogenized in 200 μl RIPA
buffer (10 mM Tris/Cl pH7.5, 150 mMNaCl, 0.5 mM EDTA, 0.1% SDS, 1% Triton X-100, 1%
Deoxycholate), supplemented with 1 μg/μl DNaseI, 2 mMMgCl2, 2 mM PMSF, 1x mammalian
protease inhibitor mix M (Serva) by repeated pipetting for 30 min on ice. After a centrifugation
step (10 min at 17.000 x g), the soluble fraction was adjusted to 500 μl with a dilution buffer (10
mM Tris/Cl pH 7.5, 150 mMNaCl, 2 mM PMSF, 1x mammalian protease inhibitor mix M
(Serva)) and incubated with 25 μl of the PARP1 nanotrap for 1 h in an end-over-end rotor at
4°C. As a negative control, a non-related nanobody coupled to 4% cross-linked agarose
(GFP-Trap or RFP-Trap) were used. The bead pellet was washed two times in 500 μl dilution
buffer. After the last washing step, the beads were transferred to a new cup, resuspended in 2x
SDS-sample buffer (120 mM Tris/Cl pH 6.8; 20% glycerol; 4% SDS, 0.04% bromophenol blue;
10% β-mercaptoethanol) and boiled for 10 min at 95°C. Samples (1–2% input, 1–2% flow-
through, 25–50% bound) were analyzed by SDS-PAGE followed by western blotting.
SDS-PAGE and immunoblotting
Denaturing polyacrylamid gel electrophoresis (SDS-PAGE) was performed according to stan-
dard procedures. Proteins were transferred from SDS gels to nitrocellulose membranes (Bio-
Rad) by semi-dry blotting and subsequently probed with different antibodies. Blots were
scanned on the Typhoon-Trio laser scanner (GE Healthcare) and quantitatively analyzed with
ImageJ software (http://imagej.nih.gov/ij/).
In vitro synthesis of pADPr polymers
pADPr polymer synthesis was performed according to the protocol from [25], with modifica-
tions detailed in [23, 26]. Here, pADPr polymers were synthesized using endogenous hPARP1
immobilized on PARP1 nanotrap and compared with the pADPr polymer synthesis catalyzed
by “free” recombinant hPARP1 purified from E. coli.
Surface plasmon resonance
Affinity measurements with Biacore T200 (GE-Healthcare) were kindly conducted by PD Dr.
Ralf Heermann at the LMUMunich. SPR sensorgrams were subsequently recorded using the
Biacore T200 Control software 1.0 and the resulting data was analyzed with the Biacore T200
Evaluation software 1.0. The PARP1 nanobody was captured on a carboxymethyldextran chip
(Xantec) via its C-terminal His6-tag by immobilizing an anti-His antibody (His Capture Kit
28-9950-56, GE Healthcare) through standard covalent amino-coupling to the chip surface.
Recombinantly purified hPARP1 was passed over the chip in seven different concentrations
from 10 nM to 1000 nM, with the lowest concentration injected twice as internal control. The
hPARP1 injection time was 3 min, followed by a dissociation time of 10 min. The surface was
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regenerated with 10 mM glycine pH 1.5 for 30 sec followed by a stabilization period of 10 sec.
The surface of the flow cell 1 was used to generate blank sensorgrams for substraction of bulk
refractive index background. The reference sensorgrams were normalized to a base line of 0.
Peaks in the sensorgrams at the beginning and the end of the injection emerged from the run
time difference between the flow cells of the chip.
Cells culture and transfections
HEK293T, HeLa, HT1080, MCF7, U2OS, PC3 and BHK cells were cultivated according to
standard protocols. Briefly, growth media consisted of DMEM (high glucose, pyruvate, L-Glu-
tamine) supplemented with 10% fetal calf serum (FCS) and antibiotics. Cells were trypsinized
for passaging and cultivated at 37°C in a humidified chamber with a 5% CO2 atmosphere. Plas-
mid-DNA was transfected with Lipofectamine1 2000 (Life Technologies) according to the
manufacturer´s protocol. HeLa cells stably expressing the PARP1 chromobody were generated
by transfection of the PARP1 chromobody vector (PARP1 VHH fused to TagRFP) and selec-
tion of resistant clones with G418 (1 μg/μl) followed by single-clone cell sorting by FACS. For
live-cell imaging, the cells were cultivated in DMEM without phenol red and supplemented
with 5% FCS and 10 mM sterile HEPES (Sigma).
Resazurin assay
To test an overall impact of the chromobody on cell viability and metabolic status, untrans-
fected and transfected HeLa cells 16 h post-transfection with the PARP1 chromobody plasmid
were incubated for 24 h in cell culture medium containing resazurin (alamarBlue1, AbD Sero-
tec). The assay was performed and evaluated according to the manufacturer’s protocol. Absor-
bance was measured at 570 nm and 600 nm with a spectrophotometer (Multiskan™ Go,
Thermo Scientific).
Cell fixation and immunocytochemistry
For end-point analysis, cells were fixed with 3.7% formaldehyde in PBS for 10 min at RT. For
detection of pADPr polymers with immunofluorescence, HeLa cells expressing/not expressing
PARP1 chromobody grown on glass coverslips, were treated with 10 mMH2O2 (Sigma) for 10
minutes, fixed with ice-cold methanol/acetone (1:1) and incubated with anti-pADPr antibody
(clone 10H, Santa Cruz) followed by secondary antibody. Subsequently, nuclei were stained
with DAPI (Invitrogen).
Fluorescent Two-Hybrid assay (F2H1)
Cell-based F2H1 protein-protein interaction assay was carried out with F2H Kit Basic (Chro-
moTek) according to manufacturer’s instructions.
Microscopy and image analysis
Epifluorescence imaging was performed using a Leica wide-field fluorescence microscope
equipped with a 20x objective (Leica). F2H and HCA images were acquired with the InCell
Analyzer 1000 (GE Healthcare) from 30 positions per well in an automated fashion. For evalu-
ation of nucleoli, automated image analysis was carried out with an IN Cell Analyzer 1000
Workstation 3.5 (GE Healthcare). “Multi-target analysis” segmentation was performed to seg-
ment nuclei (based on their fluorescent intensity, size and shape in the DAPI channel), cells
(“collar” in RFP channel) and organelles (nucleoli in the nuclei in RFP channel, based on the
size). This allowed identification of morphologically appropriate nuclei, defining cytoplasmic
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area around the nuclei and nucleoli in the nuclei. Cell-by-cell analysis was performed for at
least 100 cells stably expressing PARP1 chromobody per well. Percentage (%) of cells with
nucleoli was calculated by normalizing the number of cells with more than one nucleolus to
the total number of cells with PARP1 chromobody signal.
Laser microirradiation
Laser microirradiation live-cell experiments were carried out on an UltraView Vox spinning
disc microscope with integrated FRAP PhotoKinesis accessory (Perkin Elmer) assembled to an
Axio Observer D1 inverted stand (Zeiss) and using a 63x/1.4 NA Plan-Apochromat oil immer-
sion objective. The microscope was equipped with a heated environmental chamber set to
37°C. Fluorophores were excited with 561 nm solid-state diode laser lines. Confocal image
series were recorded with 14-bit image depth, a frame size of 256 × 256 pixels and a pixel size
of 110 nm. Microirradiation was carried out with a 405 nm diode laser set to 100% emission.
Preselected spots of ~1 μm in diameter within the nucleus were irradiated for 1 s. Before and
after microirradiation, confocal image series of one mid z-section were recorded at 1 s time
interval (5 or 9 pre-irradiation and 100 or 130 post-irradiation frames). For evaluation of the
recruitment kinetics, fluorescence intensities of the irradiated region were corrected for back-
ground and normalized to the pre-irradiation values. Data from 10–14 microirradiated cells of
each cell type were averaged and plotted.
Carbon ion beammicroirradiation
Carbon ion microirradiation was performed at the Munich ion microbeam SNAKE facility
(Supraleitendes Nanoskop für Angewandte Kernphysikalische Experimente, Maier-Leibnitz-
Laboratory, Garching, Germany) [27–29]. For irradiation and live-cell imaging, HeLa cells
were transfected with the PARP1 chromobody and re-seeded into live-cell imaging cell con-
tainers, where cells grow on a BC418 plastic scintillator [28, 30]. Cells were cultivated in phenol
red free medium supplemented with 2.5 mMHEPES and 0.25 mM Trolox. Carbon ions of 55
MeV total energy with a LET in water of 310 keV/μm were used in this work (count rate 1.5
Hz). Individual cell nuclei were irradiated with defined numbers of ions (30 or 300) per dot in
five-dot irradiation patterns as described [27]. Distance between dots was 3 μm. About ten
nuclei were targeted in a single irradiation, which takes about 1 s for 30 ions per dot or about
10 s for 300 ions per dot. Image acquisition was performed with an inverse epifluorescence
microscope (Zeiss Axiovert 200M Z1) using a Zeiss Plan Apochromat 40x/0.95 objective (Korr
Ph3 M27) and the software AxioVision 4.6 and an AxioCamMr3 camera. Cell chambers were
kept at 37°C during image acquisition.
Results
PARP1 nanobody efficiently immunoprecipitates endogenous hPARP1
We isolated a nanobody against human PARP1 from an immune alpaca VHH library (see
Materials and Methods, PARP1 nanobody is available via MTA). In a first approach, we tested
the performance of this nanobody to precipitate endogenous PARP1. To this end, we generated
an affinity resin, further referred to as PARP1 nanotrap, by covalently coupling the purified
nanobody to functionalized agarose beads via internal primary amino groups. We incubated
the PARP1 nanotrap with the soluble fraction of a whole-cell lysate of human embryonic kid-
ney cells (HEK293T). Subsequently we analyzed the input, non-bound and bound fractions by
SDS-PAGE followed by Coomassie Blue staining or immunoblotting with anti-PARP1 anti-
body. The results show that PARP1 nanotrap efficiently precipitates endogenous human
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PARP1 protein with the expected size of ~113 kDa (Fig 1A). The monoclonal anti-PARP1 anti-
body also detects several smaller degradation bands in the bound lane.
Further we measured the affinity of the purified PARP1 nanobody to the recombinant
human PARP1 (hPARP1) using Biacore surface plasmon resonance (SPR) technology (GE
Healthcare). After immobilizing the PARP1 nanobody on the chip association/dissociation
rates were measured by injecting serial dilutions of seven different concentrations (10 nM–
1000 nM) of recombinant hPARP1. We determined that the PARP1 nanobody affinity (KD
value) lies in the low nanomolar range of ~ 6.9 nM (Fig 1B), which correlates with the high
immunoprecipitation ability of the PARP1 nanotrap observed in the pull-down experiments.
PARP1 nanobody is restricted in selectivity across the PARP family and
in species reactivity
The human PARP proteins share a conserved catalytic domain, the so-called PARP-signature
region. Hence, we asked whether PARP1 nanobody recognizes other abundant members of the
PARP family. For this, GFP-fusions of hPARP1, hPARP2, hPARP3 and hPARP9 were
expressed in HEK293T cells and subjected to pull-down experiments using the PARP1 nano-
trap (Fig 2A). The analysis shows that the PARP1 nanotrap specifically precipitates GFP-
hPARP1, whereas no binding of GFP-hPARP9 is detectable. Regarding the weak signal in the
bound fraction of GFP-hPARP2 and GFP-hPARP3 we speculate that the slight pull-down of
GFP-hPARP2 and GFP-hPARP3 results rather from co-immunoprecipitation of hPARP2 and
hPARP3 with endogenous hPARP1 than from direct binding of the PARP1 nanotrap to
hPARP2 and hPARP3 (Fig 2A). This speculation is supported by previous observations
Fig 1. Immunoprecipitation performance and affinity of the PARP1 nanobody. (A) Immunoprecipitation of endogenous hPARP1 from whole-cell lysates
of HEK293T cells with PARP1 nanotrap. Input (I), flow-through (FT) and bound (B) fractions were analyzed by SDS-PAGE followed by Coomassie Blue
staining (left) and western blotting with anti-PARP1 antibody (right). (B) Affinity measurement of the PARP1 nanobody with Biacore SPR. The sensorgrams
for the nanobody at different concentrations of hPARP1 are indicated.
doi:10.1371/journal.pone.0151041.g001
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describing PARP1 to interact with PARP2 [31, 32] and hPARP3 [33, 34]. Since the PARP1
enzyme is characterized by a relatively high sequence homology across different mammalian
species, we examined cross-species reactivity of the PARP1 nanobody. To this end, we per-
formed immunoprecipitations incubating the PARP1 nanotrap with soluble protein fractions
of whole-cell lysates either derived from human embryonic kidney cells (HEK293T), mouse
embryonic fibroblasts (MEF) or baby hamster kidney fibroblasts (BHK). Immunoblot analyses
of the bound fractions reveals that the PARP1 nanotrap exclusively recognizes human PARP1
(shown in Fig 1A for endogenous hPARP1 and in Fig 2A for overexpressed GFP-hPARP1), but
neither mouse nor hamster PARP1 (Fig 2B).
The epitope of the PARP1 nanobody is localized within the DNA-binding
domain of hPARP1
To narrow down the binding region of the PARP1 nanobody, the hPARP1 protein was geneti-
cally fragmented into three major domains: a DNA-binding domain (DBD), an
Fig 2. Determination of the PARP family selectivity and species reactivity of the PARP1 nanobody. (A) Immunoprecipitation of GFP-tagged hPARP1
(141 kDa), hPARP2 (93 kDa), hPARP3 (87 kDa), hPARP9 (123 kDa) and GFP (27 kDa, negative control) with the PARP1 nanotrap from transiently
transfected HEK293T cells. RFP-Trap was used as control. Input (I), flow-through (FT) and bound (B) fractions were separated by SDS-PAGE followed by
immunoblotting with anti-GFP antibody. (B) Immunoprecipitation of endogenous PARP1 frommouse (MEF) and hamster (BHK) cells with the PARP1
nanotrap. The fractions were analyzed by SDS-PAGE and immunoblotting with anti-PARP1 antibody.
doi:10.1371/journal.pone.0151041.g002
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automodification domain and a catalytic domain. The individual domains were expressed in
SF9 insect cells, purified and tested for binding to the PARP1 nanotrap in pull-down experi-
ments. Immunoprecipitation revealed that only the DBD of hPARP1 was recognized by the
PARP1 nanotrap (Fig 3A) whereas no binding of the automodification or catalytic domain was
detected.
In a next step, we analyzed binding of the PARP1 nanotrap to the three individual zinc fin-
ger domains (ZnF1, ZnF2 or ZnF3) of the DBD of hPARP1. We showed that the PARP1 nano-
trap preferentially captures the zinc finger 2 region (ZnF2) of the DBD (Fig 3B). Whereas no
binding to ZnF1 or the WGR domain (part of the catalytic domain, served as negative control)
was observed, we detect a weak binding to ZnF3. This could be a hint that the PARP1 nano-
body recognizes an extended three-dimensional epitope within the DBD.
These findings indicate that the epitope of the PARP1 nanobody is predominantly localized
within the ZnF2 region of the DNA-binding domain of human PARP1. Most interestingly,
sequence alignments of ZnF2 between human, mouse or hamster revealed only three positions
with different amino acid residues (positions 161, 188, and 189) (S1A Fig). To test whether
these residues form an essential part of the nanobody epitope, we performed site-directed
mutagenesis turning the human ZnF2 into a hamster/mouse ZnF2. Subsequently we tested the
mutated ZnF2 in pull-down experiments with the PARP1 nanotrap (S1B Fig). Analysis of the
bound fractions showed that the mutation of the three selected amino acids within the human
ZnF2 resulted in an approximately seven fold decrease of the binding to the PARP1 nanotrap
Fig 3. Epitopemapping of the PARP1 nanobody by immunoprecipitation of hPARP1 domains. (A) Schematics depicts hPARP1 domain structure:
DNA-binding domain (45 kDa), automodification domain (19 kDa) and catalytic domain (58 kDa). Purified recombinant hPARP1 domains were subjected to
immunoprecipitation with the PARP1 nanotrap Input (I), flow through (FT) and bound (B) fractions were analyzed by SDS-PAGE followed by Coomassie Blue
staining. (B) GFP- or mCherry-tagged hPARP1 domains were transiently expressed in HEK293T cells: full DNA-binding domain (DBD), DBD constituting
zinc fingers (ZnF1, ZnF2, ZnF3), as well as the WGR domain (part of the catalytic domain). The cells were lysed and immunoprecipitated with the PARP1
nanotrap and RFP-Trap or GFP-Trap as control. The fractions were subjected to SDS-PAGE followed by immunoblotting with anti-GFP or anti-RFP antibody.
doi:10.1371/journal.pone.0151041.g003
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(S1C Fig). This data suggests that the amino acids 161, 188, and 189 within the ZnF2 are
involved in the epitope recognition by the PARP1 nanobody.
Nanobody-bound hPARP1 retains its enzymatic activity
To test the effect of nanobody binding on the catalytic activity of PARP1, we developed an in
vitro on-bead poly(ADP-ribosyl)ation assay. We used the PARP1 nanotrap for one-step pull-
down of endogenous hPARP1 from HEK293T cells. Subsequently, the bound protein was
directly used for in vitro poly(ADP-ribosyl)ation followed by pADPr chain extraction. After
extraction, the protein-free pADPr chains were analyzed for UV-absorbance and subjected to
20% native gel electrophoresis followed by silver staining.
Both, absorbance spectra (S2 Fig) and gel electrophoresis (Fig 4) showed that the endoge-
nous hPARP1 bound to the nanotrap was able to synthesize pADPr polymers. We detected a
comparable pADPr chain pattern in the reactions performed with the nanotrap-bound endog-
enous hPARP1 as well as with the purified recombinant hPARP1 used as a positive control. No
pADPr chains were detected in the internal control samples without NAD+ as substrate or in
samples obtained with an unrelated nanotrap (GFP-Trap). These results indicate that the
nanobody-bound hPARP1 retains its enzymatic activity.
PARP1 chromobody specifically recognizes hPARP1 in live cells
Next, we asked whether the PARP1 nanobody is able to recognize its target not only in vitro,
but also in its native cellular environment. To detect endogenous PARP1 within living cells, we
fused the coding sequence of the nanobody to the red fluorescent protein TagRFP, generating a
Fig 4. On-bead pADPr chain synthesis with the endogenous hPARP1 immunoprecipitated with the
PARP1 nanotrap.Gel electrophoresis and silver staining of pADPr fractions from in vitro synthesis. Lanes
1–7: commercially available pADPr chains (lane 1, control); reaction with the purified recombinant hPARP1
with NAD+ (lane 2) or without NAD+ (lane 3); on-bead reaction with PARP1 nanotrap-precipitated
endogenous hPARP1 with NAD+ (lane 4) or without NAD+ (lane 5); on-bead reaction with GFP-Trap with
NAD+ (lane 6) or without NAD+ (lane 7).
doi:10.1371/journal.pone.0151041.g004
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so-called PARP1 chromobody. Upon intracellular expression, the PARP1 chromobody
becomes visible and can be analyzed using fluorescence microscopy.
In a first step, we investigated whether the PARP1 chromobody recognizes hPARP1 intracel-
lularly. To this end, we performed a Fluorescent Two-Hybrid (F2H) assay [35, 36]. This live-cell
protein-protein interaction assay relies on a tethering strategy, where a GFP-fused bait is immo-
bilized at a particular protein interaction platform (“spot”) in the nucleus of genetically engi-
neered BHK cells (F2H-BHK). To analyze the chromobody binding, we co-transfected different
GFP-tagged bait proteins and the PARP1 chromobody pairwise into these F2H-BHK cells.
Here, different GFP-hPARP fusion proteins served as a bait, whereas the PARP1 chromobody
fused to TagRFP served as a prey. The cells co-expressing both bait and prey were evaluated for
co-localization of green (GFP-tagged constructs) and red (chromobody) fluorescent signals by
microscopy. Image analysis revealed that the PARP1 chromobody co-localized with GFP-
hPARP1, which was enriched at the “spot” in BHK-F2H cells (Fig 5). When GFP alone was
enriched at the “spot”, the PARP1 chromobody showed no binding, but a disperse distribution
within the nucleus and, to a lesser extent, in the cytoplasm. In accordance with our biochemical
findings, the F2H1 assay revealed no binding of the PARP1 chromobody to GFP-fusions of
hPARP2, hPARP3 or hPARP9. Furthermore, the PARP1 chromobody recognized the GFP-
tagged ZnF2 domain but not the mutated ZnF2-GFP (G161T, A188S and T189A). These find-
ings indicate that PARP1 chromobody is functional upon expression within living cells.
In addition, we tested intracellular binding properties of the PARP1 chromobody biochemi-
cally by performing intracellular immunoprecipitation [17]. We used the TagRFP-tag of the
PARP1 chromobody as an affinity tag for pull-downs with the RFP-affinity resin (RFP-Trap).
We prepared soluble protein fractions of whole-cell lysates derived from HeLa cells stably
expressing PARP1 chromobody (fused to TagRFP). As a negative control, we used HeLa cells
Fig 5. Intracellular F2H analysis of the PARP1 chromobody. BHK-F2H cells were pairwise co-transfected with the PARP1 chromobody fused to TagRFP
and one of the GFP-tagged bait constructs: GFP alone, GFP-hPARP1, GFP-hPARP2, GFP-hPARP3, GFP-hPARP9, wild-type ZnF2-GFP and ZnF2mut-
GFP. The cells were fixed, stained with DAPI and subjected to fluorescence microscopy. Upper row, green channel: GFP-fusion proteins are enriched at the
“spot” in the nuclei of transfected BHK-F2H cells (arrows). Middle row, red channel: binding of the PARP1 chromobody to the full-length GFP-hPARP1 and to
the wild-type ZnF2-GFP is visible as local enrichments of the red fluorescent signals (arrows). Neither interaction of the PARP1 chromobody with hPARP2, 3,
or 9, nor interaction with the mutant ZnF2mut-GFP construct (G161T, A188S and T189A) can be observed. Co-transfection with GFP (first column) served as
negative control to exclude non-specific binding of the PARP1 chromobody to GFP. Scale bar, 5 μm.
doi:10.1371/journal.pone.0151041.g005
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expressing only TagRFP. Subsequently, we incubated the soluble protein fractions with the
RFP-Trap to precipitate the PARP1 chromobody in complex with endogenous PARP1 and
analyzed the bound fraction by immunoblotting using antibodies specific for TagRFP and
PARP1 (Fig 6). The data showed that the PARP1 chromobody and the TagRFP protein were
highly enriched in the bound fraction. In addition, endogenous hPARP1 was co-immunopre-
cipitated with the PARP1 chromobody but not with the TagRFP alone. From these results we
conclude that the PARP1 chromobody specifically binds endogenous PARP1 upon intracellu-
lar expression.
PARP1 chromobody enables dynamic visualization of the endogenous
PARP1 localization in live human cells
To determine whether the intracellular expression of the hPARP1 chromobody permits visuali-
zation of the endogenous hPARP1, we further analyzed subcellular localization of the PARP1
chromobody. When co-transfected in HeLa cells, the PARP1 chromobody co-localizes with
the GFP-tagged hPARP1 in the nucleoplasm and nucleoli (Fig 7A). Similarly, when transfected
alone, the PARP1 chromobody was localized predominantly to the nucleus with enrichment in
the nucleoli (Fig 7B and 7C), recapitulating localization of the endogenous hPARP1 described
in the literature [37–39]. This observation suggests that the chromobody is recruited to endoge-
nous hPARP1 and does not bind non-specifically to other cellular structures. The cytoplasmic
background of the chromobody might be due to unbound chromobody upon overexpression.
Indeed, HeLa cells stably expressing lower levels of PARP1 chromobody almost totally lacked
the chromobody signal in the cytoplasm (data not shown).
Whereas in all tested human cell lines (HeLa, HT1080, MCF7, U2OS, HEK293T, PC3) the
chromobody signal was localized in the nuclei and nucleoli, in non-human cell lines (mouse
MEFs or hamster BHK) the chromobody signal was dispersed in the cytoplasm and, to a lesser
extent, in the nucleus (S5 Fig, left column). This data correlates well with our biochemical anal-
ysis indicating the specificity of the chromobody to human PARP1, but not to mouse or ham-
ster PARP1.
Fig 6. Endogenous hPARP1 co-precipitates together with the intracellularly expressed PARP1
chromobody. PARP1 chromobody fused to TagRFP was precipitated using the RFP-affinity resin
(RFP-Trap) from a whole-cell lysate of HeLa cells stably expressing the chromobody. TagRFP-transfected
HeLa cells served as negative control for non-specific binding. Input (I), flow-through (FT) and bound (B)
fractions were subjected to SDS-PAGE and immunoblotting with anti-PARP1 antibody, followed by anti-
TagRFP antibody and anti-GAPDH antibody as loading control.
doi:10.1371/journal.pone.0151041.g006
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We further asked whether the PARP1 chromobody can be applied to trace the dynamics of
PARP1 subnuclear localization. It has been shown in the past, that treatment of cells with
rRNA transcription inhibitors or DNA damaging agents induces PARP1 delocalization from
nucleolus to nucleoplasm [13–15, 40]. However, those results were based on immunofluores-
cence studies or overexpression of fluorescently labeled PARP1. Therefore, we sought to visual-
ize this translocation at endogenous level using the PARP1 chromobody. To monitor
delocalization of the endogenous, nucleolar hPARP1 in living cells, HeLa cells transiently
expressing the PARP1 chromobody were incubated with the following rRNA transcription
inhibitors: camptothecin [41, 42], actinomycin D [43–46] and 4-NQO [47, 48]. Cells overex-
pressing TagRFP-hPARP1 or TagRFP alone were used as positive and negative controls respec-
tively. Real-time image acquisition was performed during the 2 h incubation, followed by
additional 2 h after changing to compound-free medium. The results show a clear alteration of
the nucleolar chromobody signal upon treatment with camptothecin, actinomycin D or
4-NQO (Fig 7D–7F, also S1 Video). The signal in the nucleoli of the cells expressing
Fig 7. PARP1 chromobody enables visualization of hPARP1 in human HeLa cells. (A) PARP1 chromobody fused to TagRFP (red) co-localizes with
GFP-PARP1 (green) in nucleoli and nucleoplasm. (B-C) PARP1 chromobody fused to TagGFP (B, green) or fused to TagRFP (C, red) visualizes
endogenous hPARP1 in nucleoli and nucleoplasm. Cells were fixed, stained with DAPI (blue) and subjected to epifluorescence imaging. Scale bar, 10 μm.
(D-F) Live-cell imaging with the PARP1 chromobody upon compound treatment. HeLa cells transiently expressing either PARP1 chromobody, TagRFP-
hPARP1 or TagRFP alone were treated for 2 h with 10 μM camptothecin (D), 0.01 μM actinomycin D (E), or 0.01 μM 4-NQO (F). After subjecting cells to
incubation with the compounds, cells were washed and allowed to recover for another 2 h. Time-lapse epifluorescence imaging was carried out in an
automated fashion every 15 min during treatments and during recovery. The panels show selected frames of the cells before treatments, after 2 h of
treatment and after 2 h of recovery. Scale bar, 5 μm.
doi:10.1371/journal.pone.0151041.g007
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fluorescently labeled hPARP1 (TagRFP-hPARP1) was also decreased. However, a slight nucle-
olar pattern of TagRFP-hPARP1 was still detectable after 2 h of treatment, which could be
explained by the non-physiologically high expression level of the TagRFP-hPARP1. Upon 2 h
of recovery, the nucleolar pattern of both chromobody and TagRFP-hPARP1 was completely
restored in camptothecin treated cells, but not in actinomycin D and 4-NQO treated cells (Fig
7D–7F, also S1 Video). This data correlates well with the described mode of action of these
compounds: camptothecin inhibits processing of ribosomal precursor RNA and it’s action is
rapidly reversible [49], whereas actinomycin D-treated cells need a 24 h period to recover their
ability to synthesize RNA [50]. In addition to inhibiting rRNA-synthesis, 4-NQO induces
DNA damage, and it has been shown previously, that a 24 h recovery period is needed to repair
70% of the DNA damage [51]. No signal alteration was observed in the TagRFP-expressing
control cells.
In order to be suitable for live-cell imaging and target monitoring, the chromobody’s influ-
ence on the target function and cell viability should be negligible. With a resazurin assay, we
could show that the chromobody does not have any significant impact on cell viability and
metabolic status (S3 Fig). Further, we demonstrated that the intracellular PARP1 chromobody
expression does not detectably affect the enzymatic activity of the endogenous hPARP1. The
pADPr-antibody staining of the H2O2-treated cells shows a typical dotted nuclear pattern both
in PARP1-chromobody expressing HeLa cells, as well as in HeLa cells without the chromobody
(S3 Fig), which correlates well with our biochemical data. No pADPr pattern could be detected
in the untreated cells (control).
Next, we tested the PARP1 chromobody for visualization of redistribution of endogenous
hPARP1 in automated compound profiling. For this, HeLa cells stably expressing PARP1 chro-
mobody at a uniform level were seeded in 96-well plates and treated with different concentra-
tions of 4-NQO, actinomycin D, camptothecin and H2O2 for 4 h (S4 Fig). After the treatment,
the cells were fixed, stained with DAPI, and subjected to automated high content imaging
determining the percentage of cells with PARP1 in nucleoli before (0 μM) and after (0.01 μM–
1 mM) treatment. Quantitative analysis revealed that 4-NQO and actinomycin D are very
potent at very low doses of 0.01 μM, at which they deplete the chromobody signal from the
nucleoli. Camptothecin is increasingly effective starting with the dose 0.01 μM up to 100 μM.
Treatment with H2O2 affected the nucleolar signal only when applied in toxic amounts
(100 μM and 1 mM). This demonstrates that the PARP1 chromobody enables detailed analysis
and comparison of potencies of chemical compounds to redistribute endogenous PARP1 in
live human cells.
PARP1 chromobody visualizes recruitment of hPARP1 to DNA lesions
Finally, we analyzed whether the PARP1 chromobody visualizes the recruitment of the endoge-
nous hPARP1 on DNA lesions upon microirradiation. Firstly, we applied an UV laser, which
mainly provokes a photochemical reaction through absorption of the transferred energy that
induces various DNA lesions including single and double-strand breaks [52, 53]. To visualize
recruitment of the endogenous hPARP1 to DNA damage sites, we transiently expressed the
PARP1 chromobody in different human cell lines: HeLa, HT1080, MCF7, U2OS, PC3, and
HEK293T. Upon expression of the chromobody, the cells were subjected to irradiation using a
focused 405 nm UV laser to induce DNA damage sites at preselected spots which a defined size
(1 μM) within the nuclei. Before and after microirradiation, confocal image series of one mid z-
section were recorded at 1 s time interval with 9 pre-irradiation and 100 post-irradiation
frames. Upon microirradiation, the PARP1 chromobody visualizes a rapid recruitment and
accumulation of the endogenous hPARP1 protein at the DNA damage sites in all tested human
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cell lines (selected cell lines shown in Fig 8A, S2 Video, the complete panel is shown in S5 Fig).
Overexpression of GFP-hPARP1 was used as a positive control for visualization of the DNA
lesions and displayed similar recruitment kinetics as the chromobody (S6 Fig).
We further tested the PARP1 chromobody for visualization of PARP1 recruitment to DNA
double-strand breaks induced by carbon ion microirradiation at the Munich microprobe
SNAKE [28, 29]. The advantage of the ion microirradiation is that it creates DNA double-
strand breaks in quantitatively predictably way [54–56], whereas the UV-laser irradiation
induces an artificial composition of various types of poorly characterized DNA damage [56].
To semi-quantitatively estimate the minimum damage load necessary for visible PARP1
Fig 8. Recruitment of endogenous PARP1 to the DNA damage sites as visualized by the PARP1 chromobody in live human cells. (A) Live-cell
imaging of laser-microirradiated (405 nm laser, 100% power, 1 s) human HeLa, human PC3 cells and hamster BHK cells transiently expressing PARP1
chromobody. Time-lapse imaging was carried out at 1 frame per second with the spinning disc microscope acquiring 9 pre-irradiation and 100 post-irradiation
frames. Selected time-frames are shown, yellow circles depict the regions of microirradiation (Ø 1 μm), yellow arrow-heads mark the sites before and after
irradiation. Scale bar, 5 μm. (B) Live-cell imaging of carbon ion-irradiated HeLa cells (300 ions per point) transiently expressing PARP1 chromobody. The
cells were irradiated with accelerated 55 MeV (total energy) carbon ions (LET in water: 310 KeV/μm). At 0 s yellow dots in a cross-shape mark the
prospective sites of irradiation. After irradiation images were acquired every ~4 s. Selected time points are shown. Scale bar, 10 μm.
doi:10.1371/journal.pone.0151041.g008
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accumulation, we took advantage of the highly focused beam, which can deliver a pre-defined
number of ions on a spot of about 1 μm diameter [27, 30]. In these experiments, HeLa cells
transiently expressing the PARP1 chromobody were subjected to carbon ion irradiation with
30 and 300 ions per point (corresponding to about 315 or 3150 double-strand breaks per point,
respectively) [27] at preselected spots. After irradiation, a rapid accumulation of the PARP1
chromobody at DNA damage sites can be visualized which reflects the recruitment of endoge-
nous PARP1. The cross-like irradiation pattern can be detected after ~7–10 s in cells irradiated
with 300 ions per point (Fig 8B, S3 Video), while no recruitment of endogenous hPARP1 was
observed in cells irradiated with 30 ions or less per point (data not shown). The spots represent
the accumulated, endogenous hPARP1 at the sites of damaged chromatin. The signal of the
PARP1 chromobody is only transiently present at the DNA repair sites. After gradually fading
out it is hardly detectable after 420 s.
Discussion
Here we describe a new biosensor based on a single-domain antibody derived from an alpaca
immune library that allows detection and dynamic tracing of one main component of the DNA
repair machinery—human PARP1 –in biochemical assays and living cells. In this study we per-
formed a detailed characterization of the binding properties of the PARP1 nanobody which is
essential for intended downstream applications in proteomics or live-cell imaging. We could
demonstrate that the PARP1 nanobody specifically recognizes and binds the human PARP1
protein. Since nanobodies have only three hypervariable regions (CDRs), compared to antibody
formats derived from conventional IgGs, these binders preferably recognize and bind conforma-
tional epitopes e.g. formed by enzymatic pockets of regulatory domains [57, 58]. Consequently,
binding of nanobodies often interferes with the function of the targeted antigen [59–61]. Epi-
tope mapping of the PARP1 nanobody revealed a binding site within the zinc finger 2 of the
DNA-binding domain of hPARP1. Comparison of ZnF2 domains of mouse or hamster PARP1
proteins, which are not recognized by the PARP1 nanobody, gave rise to the assumption that
amino acids Gly161, Glu188 and Thr189 are essential for forming a conformational epitope.
ZnF2, together with ZnF1, appears to be involved in binding to strand breaks, albeit not in
PARP1 activation upon binding to damaged DNA [6]. Still, binding of the nanobody seems not
to affect binding of hPARP1 to DNA as shown by efficient recruitment of the PARP1 chromo-
body to DNA lesions (Fig 8, S5 and S6 Figs, S2 and S3 Videos). In addition, we demonstrate that
binding of the PARP1 nanobody does not affect the PARylation activity of hPARP1 neither in
vitro, nor in vivo. Our biochemical PARylation assays showed that PARP1 retains its catalytic
activity when bound by the PARP1 nanotrap (affinity matrix from PARP1 nanobody immobi-
lized on agarose beads) (Fig 4, S2 Fig) and cellular immunocytochemistry revealed that PARyla-
tion takes place upon H2O2 treatment of cell expressing the PARP1 chromobody (S3 Fig).
The sensitivity of the PARP1 nanobody further relies on its high affinity (KD ~6.9 nM for
hPARP1). In comparison to other recently reported nanobodies, such as the p53 nanobody,
which shows a 100 fold lower affinity (KD ~1 μM) [59], the PARP1 nanobody belongs to the
group of high-affinity binders. For proteomic approaches we tested the PARP1 nanobody as an
affinity reagent. We generated a PARP1 nanotrap by covalently coupling the monovalent
PARP1 nanobody to an immobilizing matrix and demonstrated that it enables a fast and effi-
cient one-step immunoprecipitation of the hPARP1 protein from human cell lysate (Fig 1).
Such affinity purification reagents are highly favorable due to the properties of the nanobodies
regarding stability, chemical resistance, long shelf-life and robust binding performance [24, 62].
In addition, our data shows that the nanobody retains its binding specificities upon intracel-
lular expression (Figs 5 and 6). Until now, for investigation of the subcellular PARP1
PARP1 Nanobody for Analysis of Endogenous hPARP1
PLOSONE | DOI:10.1371/journal.pone.0151041 March 7, 2016 16 / 23
localization, the two main techniques were available: immunostaining and ectopic expression
of fluorescently tagged PARP1. However, artificially introduced ectopic fusion proteins can
lead to phenotypical changes, i.e. the chimeric fusion protein can behave differently than its
endogenous equivalent [20, 63]. Furthermore, when a vector-based rather than a knock-in
strategy is chosen, transfected cells already express the endogenous variant of the protein and
the ectopic expression changes the intracellular amount of available protein. The major draw-
back of the immunostaining approach is that in order to label an intracellular target, cells have
to be fixed and permeabilized, which is not compatible with live-cell analysis and can introduce
artifacts and aberrations [11, 12]. A recent study evaluating subcellular localization of over 500
human proteins with immunofluorescence vs. chimeric overexpression revealed frequent dis-
crepancies between the data [12]. Therefore, we asked if the PARP1 nanobody could overcome
these technical limitations and provide information about localization of the endogenous
hPARP1 in live cells without fixation and permeabilization. Upon expression of fluorescent
protein-tagged constructs of the PARP1 nanobody (PARP1 chromobody) in live mammalian
cells, the chromobody visualizes endogenous hPARP in its native intracellular environment.
In accordance to previous studies using immunofluorescence or overexpression of fluores-
cently labeled PARP1 [37, 64–66], the PARP1 chromobody signal showed a clear enrichment
in the nuclei and nucleoli, which is characteristic for PARP1. In extensive time-lapse analyses
we monitored translocation of the chromobody signal from nucleoli into nucleoplasm upon
treating cells with inhibitors of rRNA transcription (Fig 7D–7F).
We also showed that the PARP1 chromobody signal translocation can be imaged and quan-
titatively analyzed in a high content imaging approach (S4 Fig). This approach could enable
screening and HCA of PARP1-targeting compounds with respect to their effect on the subnu-
clear localization of the endogenous PARP1 in live human cells. For example, drug-induced
trapping of endogenous PARP1 at DNA lesions could be addressed directly in live human cells
with the help of PARP1 chromobody.
We further demonstrate that upon DNA damage induction by microirradiation, the PARP1
chromobody visualizes recruitment of endogenous hPARP1 enzyme to damaged DNA. These
experiments revealed that the endogenous hPARP1 is recruited to damaged DNA within sec-
onds, as we observed rapid local enrichment of the chromobody signal at the lesions after a few
seconds post-irradiation (Fig 8, S5 Fig, S2 and S3 Videos). The kinetics of hPARP1 recruitment
monitored by the chromobody is in line with the previous studies where GFP-PARP1 recruit-
ment was analyzed [67]. Also, previous reports indicate that association of PARP1 with DNA
strand breaks is transient [5, 67], and during this study we could show that the enriched chro-
mobody signal at the mircoirradiation sites fades within minutes after irradiation (Fig 8B). By
localized carbon ion irradiation we also observed that the local density of DNA lesions has to
be very high to enable detection of hPARP1 accumulation.
It is important to note that although the chromobody enables visualization of hPARP1
recruitment, it does not provide information about PARP1 enzymatic activity. For example,
upon treatment with H2O2, no pADPr-like pattern representing active sites of DNA damage
could be observed neither with the PARP1 chromobody, nor with TagRFP-hPARP1, but only
with a pADPr-specific antibody. This is in agreement with the previous studies showing that
even catalytically inactive PARP1 mutants are still recruited to DNA lesions [67].
Conclusions
In conclusion, here we characterized a novel PARP1 nanobody derived from an alpaca heavy-
chain only antibody. We showed that the nanobody is highly affine and specific to the human
PARP1 protein. In biochemical applications, PARP1 nanobody enables efficient
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immunoprecipitation of endogenous human PARP1 and its interaction partners. Furthermore,
binding of the nanobody does not disturb enzymatic activity of hPARP1 or its DNA-binding
ability. In live-cell experiments we showed that the PARP1 chromobody enables previously
impossible real-time visualization of the endogenous hPARP1 enzyme. For the first time, by use
of the PARP1 chromobody, the recruitment of the endogenous hPARP1 to the sites of DNA
damage could be observed in live cells. Being a versatile affinity reagent functional both in vitro
and in vivo, the newly developed PARP1 nanobody will contribute to further understanding of
the various PARP1 functions including the molecular role of PARP1 in DNA repair.
Supporting Information
S1 Fig. Amino acid substitutions within the human PARP1 ZnF2 domain significantly
decrease binding of the PARP1 nanotrap. (A) Amino-acid sequence alignment of the PARP1
ZnF2 domains from hamster (Mesocricetus auratus, NCBI Reference Sequence:
XP_005078195.1), mouse (Mus musculus, NCBI Reference Sequence: NP_031441.2) and
human (Homo sapiens, NCBI Reference Sequence: NP_001609.2). Differences with respect to
the human amino acid sequence are highlighted in yellow. Positions for the introduced single
mutations are highlighted in green. (B) HEK293T cells were transiently transfected with the
GFP-tagged wild-type or mutated (G161T, A188S and T189A) ZnF2 domain of hPARP1, lysed
and subjected to pull-down with the PARP1 nanotrap. Input (I), flow-through (FT) and bound
(B) fractions were analyzed by SDS-PAGE followed by immunoblotting with anti-GFP anti-
body. (C) Quantitative comparison of the immunoprecipitation efficiency of wild-type and
mutated (G161T, A188S and T189A) hPARP1 ZnF2 with the PARP1 nanotrap. Quantitative
analysis of the signal densities on western blot was performed with ImageJ; the signals in the
bound lanes were normalized to the input. Chart bars show mean ± S.D., T-test;  p<0.05;
n = 4.
(JPG)
S2 Fig. On-bead pADPr chain synthesis with immunoprecipitated endogenous hPARP1
after pull-down with the PARP1 nanotrap. Absorbance spectra of synthesized and purified
pADPr polymers are shown. Reaction with the purified recombinant hPARP1 with NAD+ (A)
or without NAD+ (B); on-bead reaction with PARP1 nanotrap-precipitated endogenous
hPARP1 with NAD+ (C) or without NAD+ (D); on-bead reaction with unrelated nanotrap
(GFP-Trap) with NAD+ (E) or without NAD+ (F) after IP.
(JPG)
S3 Fig. PARP1 chromobody expression in living cells does not significantly affect cell via-
bility or PARP1 enzymatic activity. (A) Comparison of the metabolic viability of HeLa cells
transiently expressing PARP1 chromobody and untransfected HeLa cells (nt) in resazurin
assay (alamarBlue). Percentages of viable cells after 24 h of proliferation were determined.
Chart bars show mean ± S.D., no significant differences, n = 3. (B) pADPr immunostaining (in
green) of HeLa cells stably expressing the PARP1 chromobody (in red) and HeLa cells without
chromobody (C) after treatment with 10 mMH2O2 for 10 minutes. Scale bar, 10 μm.
(JPG)
S4 Fig. High content analysis of compound potencies to delocalize hPARP1 from nucleoli
as determined based on the PARP1 chromobody signal.HeLa cells stably expressing PARP1
chromobody were treated with different concentrations of 4-NQO, actinomycin D, camptothe-
cin and H2O2 (titration series from 0.01 μM up to 1 mM) for 4 h. Subsequently, cells were fixed
with 4% formaldehyde, counterstained for DAPI, imaged and analyzed in an automated fash-
ion with the IN Cell Analyzer software. Segmentation analysis was applied and cells with/
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without PARP1 in nucleoli were counted in each well. Chart bars are mean ± S.D., T-test; 
p<0.005; n = 6.
(JPG)
S5 Fig. Monitoring of laser-induced DNA damage with PARP1 chromobody in human and
non-human cells. (A) Live-cell imaging of laser-microirradiated (405 nm laser, 100% power, 1
s) cells transiently expressing the PARP1 chromobody. Time-lapse imaging was carried out at
1 frame per second rate with a spinning disc microscope acquiring 9 pre-irradiation and 100
post-irradiation frames. Selected time-frames are shown, yellow circles depict the microirradia-
tion regions (Ø 1 μM), yellow arrow-heads mark the sites before and after irradiation. Scale
bar, 5 μm. (B) Quantitative evaluation of recruitment kinetics of endogenous hPARP1. Pre-
irradiation intensity values were normalized to 100%, no correction for photobleaching during
image acquisition was implemented. For each cell line, 10–14 cells were analyzed. Data are
mean ± S.D.
(JPG)
S6 Fig. Recruitment of GFP-hPARP1 and PARP1 chromobody to the DNA damage sites
induced by laser microirradiation.HeLa cells transiently co-transfected with GFP-hPARP1
and PARP1 chromobody (TagRFP) were subjected to confocal imaging upon microirradiation
with a 405 nm diode laser for 1 second. Time-lapse imaging was carried out at 1 frame per sec-
ond rate with a spinning disc microscope. Scale bar, 5 μm.
(JPG)
S1 Video. Live-cell movie of HeLa cells expressing PARP1 chromobody treated with 10 μM
camptothecin followed by recovery.
(GIF)
S2 Video. Live-cell movie of laser-irradiated HeLa cells transiently expressing PARP1 chro-
mobody.
(GIF)
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